Citations

Showing 10 of 108104 citations.

Abstract 10808: Prognostic Significance of Obstructive Coronary Artery Disease in Patients Admitted with Acute Decompensated Heart Failure: The ARIC Study Community Surveillance
Chunawala, Zainali , Caughey, Melissa C. , Qamar, Arman , Arora, Sameer , Pandey, Ambarish , Fudim, Marat , Vaduganathan, Muthiah , Mentz, Robert J.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10808 Get It

Background: Coronary artery disease (CAD) is a common cause of heart failure (HF). Whether the extent of coronary artery stenosis differs by HF type or prognosis for patients admitted with acute decompensated heart failure (ADHF) is uncertain. Methods: The Atherosclerosis Risk in Communities (ARIC) study conducted hospital surveillance of adjudicated HF in 4 US areas from 2005-2014. Medical histories were abstracted from the hospital record. Obstructive CAD was defined as > 49% stenosis in the left main coronary artery or >74% stenosis in the other major coronary arteries. Associations between obstructive CAD and 28-day mortality were analyzed separately for heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), adjusting for age, race, sex, year of admission, and coronary revascularization procedures. All analyses were weighted by the inverse of the sampling probability. Results: A total of 5115 patients admitted with ADHF underwent coronary angiography during the hospital visit (mean age = 72, 45% women, 28% Black, 30% HFpEF). Obstructive CAD was more prevalent with HFrEF ( Figure 1 ), whether at the left main coronary artery (16% vs 12%), left anterior descending artery (50% vs 35%), left circumflex artery (42% vs 34%), right coronary artery (45% vs 34%), or multiple coronary vessels (47% vs 34%). A similar proportion of patients with obstructive CAD underwent revascularization, irrespective of HF type (HFrEF: 55%, HFpEF: 61%). After adjustments, obstructive CAD (in any vessel) was associated with higher 28-day mortality, both for HFrEF (OR: 3.21; CI: 1.91 - 5.97) and HFpEF (OR: 3.62; 95% CI: 1.43 - 9.18) with no significant interaction by HF type ( P -interaction = 0.9). Conclusion: Patients hospitalized with ADHF and coexisting obstructive CAD are at greater risk of short-term mortality, irrespective of the HF type, warranting the need for effective interventions as well as secondary preventive measures in this population.
Abstract 10781: Improving Medication Communication Following Percutaneous Coronary Intervention
Kohlmann, Keri Q, Ring, Michael T, Fink, Angela L

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10781 Get It

Introduction: Patients undergoing percutaneous coronary intervention (PCI) acquire or continue an average of five medications specific to their intervention during hospitalization, some of which are continued for life. It has been identified that poor communication between health care professionals and patients is a contributor to medication nonadherence. The aim of this quality improvement project was to determine if the implementation of individualized medication education forms and patient-centered medication training would improve nurse-patient medication communication. Methods: Project interventions were implemented on a post-PCI telemetry unit from December 2020 to February 2021. Patients with acute coronary syndrome requiring PCI during hospitalization were surveyed on five domains at the time of discharge from October 2020 to February 2021. The five domains included: 1) medication communication 2) confidence in medication name recall 3) ability to manage medications 4) understanding of medication purposes and 5) side effect management. Results: A total of 53 patients were included in this analysis, with 28 in the pre-intervention group and 25 in the post-intervention group. Comparatively, patients in the post-intervention group reported a subjective improvement in medication communication, confidence in recalling medication names, ability to manage medications, and understanding of medication purposes and side effects when compared to patients in the pre-intervention group. Conclusion: The use of multidimensional, standardized medication education forms and medication training positively impacted medication communication between nursing and post-PCI patients.
Abstract 10726: Cardiac Resynchronization Therapy Response in Cardiac Sarcoidosis
Shabtaie, Samuel A. , Lee, Justin Z. , Cha, Yong‐Mei , Bois, John P. , Rosenbaum, Andrew , Siontis, Konstantinos C. , Mulpuru, Siva K. , Deshmukh, Abhishek , DeSimone, Christopher V. , Kapa, Suraj , AbouEzzeddine, Omar F.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10726 Get It

Introduction: Cardiac Sarcoidosis (CS) is a non-ischemic cardiomyopathy (NICM) characterized by infiltration of non-caseating granulomas involving in the heart with highly variable clinical manifestations. Cardiac resynchronization therapy (CRT) has shown significant promise in NICM, though little is known about its effectiveness in patients with CS. Hypothesis: We sought to determine if CRT improved cardiac remodeling and reduced hospitalizations in patients with CS. Methods: We retrospectively reviewed all patients with a clinical or histological diagnosis of CS who underwent CRT implantation at a Mayo Clinic site from 2000-2021. Baseline characteristics, echocardiographic parameters, heart failure hospitalization, and major adverse cardiac events (MACE) were assessed. Results: Our cohort was comprised of 55 patients with 61.8% male and a mean age of 58.7 ± 10.9 years. At baseline, 38 (69.1%) patients had isolated CS, while 17 (30.9%) had evidence of CS with extra-cardiac sarcoidosis. The overwhelming majority underwent CRT-D implantation (n=52, 94.5%) with 67.3% of implanted devices upgrades from prior pacemaker or implantable cardioverter defibrillator. At 6 months post-implantation there was no significant different in ejection fraction (34.8 ± 10.9 % vs. 37.7 ± 14.2 %, p = 0.237), left ventricular end systolic diameter (49.1 ± 9.9 mm vs. 45.7 ± 9.9 mm, p = 0.077) or left ventricular end-diastolic diameter (58.5 ± 10.2 mm vs. 57.5 ± 8.1 mm, p = 0.574). Within the first 6 months post-implantation, 5 (9.1%) patients sustained a heart failure hospitalization. At a mean follow up of 4.1 ± 3.7 years, 14 (25.5%) patients experienced a heart failure hospitalization, 11 (20.0%) underwent cardiac transplantation, 1 (1.8%) underwent LVAD implantation and 7 (12.7%) patients died. Conclusions: Our findings suggest a poor response to CRT in patients with CS with no significant evidence of reverse remodeling within 6 months and a substantial proportion of patients progressing to advanced heart failure therapies.
Abstract 10680: Unsupervised Machine Learning Clustering Identifies Phenotypes of Optimal Candidates in Mitraclip Patients
Wu, Han-Lun, Seri, Amith Reddy , Shanbhag, Anusha , Rayfield, Corbin, Wang, Yuxiang , Smith, S. M. , Fortuin, F. David , Sweeney, John P., Eleid, Mackram F. , Rihal, Charanjit S. , Holmes, David R. , Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Shen, Win K., Patel, Bhavik N. , Chao, Chieh‐Ju , Smith, Sean, Alkhouli, Mohamad , Rihal, Charanjit S. , Arsanjani, Reza

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10680 Get It

Introduction: Unsupervised machine learning (ML) can provide insight into a dataset without significant expert time for annotation and labeling, but was never used to assess the heterogeneous MitraClip population. Hypothesis: We hypothesized that unsupervised k-means ML could identify prognostically-distinct phenogroups in MitraClip patients without a priori knowledge of the dataset. Methods: Patients who underwent MitraClip (June 2014-September 2020) at Mayo Clinic sites were identified from the Mayo institutional NCDR database for baseline and follow-up data. Variables with ≥ 50% missing data were excluded. A k-means algorithm was used for clustering analysis. Input variables were grouped according to 4 distinct k-means determined clusters. Kaplan-Meier survival analysis was used to assess the survival of each cluster. Results: A total of 389 consecutive patients were included in the final analysis, and 95 unique variables were used. The mean age was 80.3±8.7 years; 256 (65.8%) were male. The mean STS MV Replace score was 9.1±5.7. Fifty-five (14.5%) patients died during the mean follow duration (185 days). Kaplan-Meier analysis showed significant survival differences among clusters (Figure 1). The cluster (cluster 2, n=120) with best survival performance (all-cause mortality 3.3%) had features of non-calcified mitral leaflets, nonischemic cardiomyopathy, and less than moderate tricuspid regurgitation. Cluster 3 (n=66) had the worst survival performance (all-cause mortality 27.3%) and opposite features than cluster 2. Conclusions: Unsupervised ML can identify distinct phenotype clusters with prognostic significance in MitraClip patients. Patients with non-calcified mitral leaflets, nonischemic cardiomyopathy, and less than moderate tricuspid regurgitation are intrinsically different from other MitraClip patients and should be considered the potential optimal candidates.
Abstract 10663: Outcomes After Heart Transplantation in Patients with Cardiac Sarcoidosis
Alnsasra, Hilmi , Doulamis, Ilias P. , Kushwaha, Sudhir S. , Álvarez, Paulino , Asleh, Rabea , Kampaktsis, Polydoros Ν. , Briasoulis, Αlexandros

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10663 Get It

Introduction: The number of patients with sarcoidosis requiring heart transplantation (HT) is on the rise. Hypothesis: The aim of this study was to evaluate outcomes of isolated HT in patients with sarcoid cardiomyopathy. Methods: Adult HT recipients were identified in the UNOS Registry between 1990 and 2020. Patients were grouped according to diagnosis. The cumulative incidences for the all-cause mortality and rejection were compared using Fine and Gray model analysis, accounting for re-transplantation as a competing risk. Moreover, we reviewed characteristics and outcomes of all HT recipients with previous diagnosis of sarcoid cardiomyopathy from a single-center. Results: A total of 30,874 HT recipients were included in the present study (n=240 sarcoidosis, n=1,431 non-ischemic restrictive cardiomyopathy, and n=29,203 non-ischemic dilated cardiomyopathy). During a total of 196,985 patient-years, all-cause mortality at the latest follow-up was not significantly different when comparing sarcoidosis to non-ischemic dilated cardiomyopathy (adjusted subhazard ratio [aSHR] 1.4, 95% confidence intervals [CI]: 0.88-2.3, p=0.15) or restrictive cardiomyopathy (aSHR 1.12, 95% CI: 0.65-1.95, p=0.67). Accordingly, multivariable analysis suggested that 1-year mortality was not significantly different between sarcoidosis and non-ischemic dilated cardiomyopathy (aSHR 1.56, 95% CI: 0.9-2.7, p=0.12) or restrictive (aSHR 1.15, 95% CI: 0.61-2.18, p=0.66) cardiomyopathy. Additionally, no differences were observed regarding 30-day mortality after HT. Data from the single-center case review showed excellent long-term outcomes with sirolimus-based immunosuppression. Conclusions: Short- and long-term outcomes after isolated HT do not seem to be inferior in sarcoid cardiomyopathy when compared to common types of non-ischemic cardiomyopathy.
Abstract 10652: Epidemiology and Outcomes of Pulmonary Hypertension in the Cardiac Intensive Care Unit
Jentzer, Jacob C. , Wiley, Brandon M. , Reddy, Yogesh N.V. , Barnett, Christopher F. , Borlaug, Barry A. , Solomon, Michael A.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10652 Get It

Introduction: Pulmonary hypertension (PH), defined as an elevated mean pulmonary artery pressure, has been consistently associated with adverse outcomes in hospitalized patients. Limited epidemiologic data exist regarding PH in the cardiac intensive care unit (CICU) population. We used transthoracic echocardiography (TTE) to describe the prevalence, etiology, and outcomes of PH in the CICU. Hypothesis: PH will be associated with higher in-hospital mortality in CICU patients. Methods: CICU patients admitted from 2007 to 2018 who had right ventricular systolic pressure (RVSP) measured via TTE within 1 day of CICU admission were included. PH was defined as an estimated RVSP >35 mmHg. Predictors of in-hospital mortality were determined using multivariable logistic regression. Results: We included 5042 patients with a mean age of 69.4±14.8 (41% females); 81.1% had an admission diagnosis of acute coronary syndrome or heart failure. PH was present in 3085 (61%); the majority (68%) of patients with PH had left heart failure, and 29% had lung disease. In-hospital mortality occurred in 8% and was higher in patients with PH (11% vs. 4%, adjusted OR 1.40, 95% CI 1.03-1.92, p =0.03). PH was associated with higher in-hospital mortality in patients with acute coronary syndrome, heart failure or cardiac arrest (all p <0.01), but not in patients with cardiogenic shock, respiratory failure or sepsis ( Figure ). In-hospital mortality increased as a function of higher RVSP in each admission diagnosis group (adjusted 1.18 per 10 mmHg higher in the entire cohort, 95% CI 1.09-1.28, p <0.001). Conclusions: PH by TTE is very common in the CICU population and remains associated with a higher risk of death during hospitalization even after adjustment. TTE assessment of right heart hemodynamics can predict mortality in CICU patients, with variability across common admission diagnoses. This highlights the importance of PH determined by TTE in hospitalized patients with cardiac critical illness.
Abstract 10648: The Presence of Iatrogenic Atrial Septal Defect Does Not Affect the Right Ventricular Strain Function in Patients with More Than Moderate Tricuspid Regurgitation
Seri, Amith Reddy , Fennellly, Evelyn, Campany, Megan , Kenyon, Courtney , Fath, Ayman R. , Smith, Sean B. , Buckner‐Petty, Skye , Rayfield, Corbin, Fortuin, David, Sweeney, John P., Mackram, Eleid F, Rihal, Charanjit S. , Pollak, Peter , Sabbagh, Abdallah El , Chao, Chieh‐Ju , Alkhouli, Mohamad , Rihal, Charanjit S. , Arsanjani, Reza

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10648 Get It

Background/Introduction: More than moderate tricuspid regurgitation (TR) at baseline is associated with worse outcome in MitraClip patients. The presence of iatrogenic ASD (iASD) may cause right-sided volume overload and lead to adverse events. However, the real effects of iASD are not well-investigated in these patients who are vulnerable to right-sided volume overload. Methods: Patients with more than moderate TR who underwent a successful MitraClip procedure in the period from June 2014 to September 2020 were identified from the Mayo institutional NCDR database. Follow-up transthoracic echocardiography (TTE) at about 1 year after the procedure was used to determine the presence of iASD, and speckle-tracking strain analysis was done. Patients were grouped according to the presence of iASD (iASD+ group vs. iASD- group) for statistical analysis. Results: A total of 141 consecutive patients were included for the final analysis (iASD+ group n=44 and iASD- group n=97). The mean age was 79.3 ± 8.8 years, and 72.3% were male. Follow-up echocardiography and speckle-tracking strain data did not show a significant difference in either left or right ventricular function in conventional echocardiographic parameters and strain. LA reservoir strain (13.7 ± 6.9 vs 11.5±7.5, P=0.0418) was the only parameter with significant difference among the two groups. Details are summarized in Table 1 . Conclusion: The presence of iASD can decompress the left atrium, but does not affect left or right ventricular strain function in MitraClip patients with more than moderate baseline TR.
Abstract 10641: Changes in Oxygen Uptake Parameters Across High-Intensity Intervals Prescribed Using Rating of Perceived Exertion in Cardiac Rehabilitation
Content, Virginia G. , Olson, Thomas P. , Hammer, Shane M. , Smith, Joshua

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10641 Get It

Introduction: High intensity interval training (HIIT) during early outpatient cardiac rehabilitation (CR) improves peak oxygen uptake (VO 2 ) and reduces mortality in patients with cardiovascular disease. In a CR setting, prescribing interval intensity using rating of perceived exertion (RPE) is more feasible than using percent of VO 2peak . Additionally, prescribing HIIT with RPE may allow for progressive changes in the VO 2 response throughout a single HIIT session. However, the acute cardiopulmonary responses during individual intervals of HIIT prescribed via RPE in CR are unknown. Hypothesis: We hypothesized that VO 2peak would increase and time-to-peak (TTP) would shorten across high-intensity intervals during a single HITT session prescribed with RPE. Methods: Patients with CAD (N=14; 2 women; 56±9 yrs; 30.46±4.7 kg/m 2 ) referred to CR after an acute coronary event completed a minimum of 25 supervised HIIT sessions during which VO 2 was measured continuously. Each HIIT session included 5 or more (6±1 sessions) 1-minute high intensity intervals (target RPE: 15-17) separated by a 3 to 5-minute low intensity interval (target RPE: <12). The first and last HIIT sessions were used for analysis. VO 2peak was defined as the highest 3-breath averaged VO 2 during or up to 1 minute following each high intensity interval. Results: RPE was 15±2 and 11±2 during the high and low intensity intervals, respectively. Compared to the first HIIT session, VO 2peak was greater during the high intensity intervals of the last HIIT session (25.4±1.5 vs. 21.8±1.1 mL/kg/min; p=0.04). During the first and last HIIT sessions, VO 2peak increased across high intensity intervals (p<0.001). Although TTP was not significantly reduced across intervals during the first HIIT session (p=0.14), TTP was reduced across intervals during the last HIIT session (first interval: 67±19 vs. last interval: 58±9 s; p<0.01). Conclusions: Prescribing HIIT with RPE resulted in increased VO 2peak across high intensity intervals within single HIIT sessions and shortened TTP during high intensity intervals across CR. These findings provide evidence for a priming effect on VO 2peak during HIIT which may contribute to greater cardiopulmonary adaptations in CAD patients.
Abstract 10629: Effect of Empagliflozin on Blood Volume Redistribution in Patients with Chronic Heart Failure and Reduced Ejection Fraction
Jensen, Jesper , Videbæk, Lars , Schou, Morten , Omar, Massar , Jensen, Jesper, Burkhoff, Daniel , Frederiksen, Peter , Kistorp, Caroline , Poulsen, Mikael Kjær , Gustafsson, Finn , Køber, Lars , Borlaug, Barry A. , Møller, Jacob Eifer

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10629 Get It

Background: The relationship between blood volume and pressure in the vascular system can be described in terms of unstressed and stressed blood volume. Stressed blood volume determines venous pressure and provides preload back to the heart, which regulates the generation of cardiac output (CO) via the Frank-starling mechanism. Whether sodium-glucose cotransporter-2 (SGLT2i) favorably modifies stressed blood volume is not known. Hypothesis: To investigate the effect of SGLT2i (empagliflozin) on the hemodynamic estimated stressed blood volume (eSBV) in HFrEF patients compared to placebo. Methods: A post hoc analysis of investigator-initiated, double-blinded, placebo-controlled, randomized trial. Seventy patients were assigned to empagliflozin of 10 mg or matching placebo once daily for 12 weeks. Patients underwent right heart catheterization at rest and during exercise at baseline and follow-up. Outcome was change in eSBV after 12 weeks of empagliflozin treatment at each level of exercise. We conducted computer-modelling simulations based on invasive hemodynamic assessment to measure eSBV. Results: HFrEF patients with mean age was 57 years, mean ejection fraction 27%, 47 (71%) on diuretics were randomized. After 12 weeks treatment exercise eSBV was significantly reduced at 0 watt, 25 watt and 25 % of maximal exercise watt, compared to placebo [(0 watt; –258 mL, 95% CI –476 to –39, p=0.021); (25 watt; –301 mL, 95% CI –561 to –40, p=0.024); and (25% of peak exercise watt; –262 mL, 95% CI –490 to –34, p=0.024)]. There was no effect on rest, or at peak exercise eSBV [(Rest; –75 ml, 95% confidence interval [CI] –279 to 130; p=0.47); and (Peak; –96 mL, 95% CI –444 to 251, p=0.59)]. This was consistent among patients with and without type 2 diabetes, etiology of HFrEF, and diuretic usage (Figure 1). Conclusion: Empagliflozin may contribute to shift blood from the effective circulatory beds to the venous reservoir in reducing filling pressure and eSBV, but maintaining CO.
Abstract 10607: Evaluating Diastolic Function by Echocardiography in a Prospective Cohort of Patients with Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL) Who Received Anthracycline-Based Chemotherapy
Tawfiq, Reema, Martinez, Juan Quintero, Cordova, Sandra, Alam, Md Mashiul, Herrmann, Joerg , Thompson, Carrie A. , Villarraga, Hector R. , Boddicker, Nicholas , Alam, Md. Mashiul , Cerhan, James R.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10607 Get It

Introduction: Anthracyclines are a first-line chemotherapeutic agent used in the treatment of lymphoma. Myocardial injury can occur with cumulative doses of 250 to 350 mg/m 2 . Echocardiography is the imaging modality for identifying cardiac dysfunction; however, identifying diastolic changes in patients who received anthracyclines is not well represented in the literature. Variables used to identify diastolic dysfunction include lateral e’, medial e’, mitral E velocity, mitral A velocity, E/A, E/e’, and left atrial volume index (LAVI). This study aims to identify if diastolic abnormalities develop in a prospective cohort of patients with HL or NHL who received anthracycline-based chemotherapy. Methods: Lymphoma patients treated with anthracyclines from 2013 to 2020 were prospectively enrolled. Echocardiography was obtained at 3-time points: before the start of chemotherapy (T1), at 3-6 months (T2), and 9-12 months (T3). Diastolic variables were measured and analyzed based on the total cumulative dose of Doxorubicin per body surface area. Those that received greater than 250 mg/m 2 and greater than 300 mg/m 2 of Doxorubicin were compared to those that did not. Statistical analysis was done using one-way ANOVA, adjusting for age and gender. Results: 151 total patients (90 males, mean age 61 + 16 years); 21 (14%) HL, 130 (85%) NHL. 114 and 66 patients received a total cumulative dose of Doxorubicin greater than 250 mg/m 2 and 300 mg/m 2 , respectively. There was no significant association with 250 mg/m2. Lateral e’ at T3 vs. T1, was lower in those that received greater than 300 mg/ m 2 compared to those received less (0.09 vs 0.10, p < 0.02) (Table 1). Conclusions: Lateral e’ decreased at 1-year follow-up in those that received higher doses of Doxorubicin. These changes in the lateral e’ could reflect early relaxation abnormalities related to anthracycline-based chemotherapy and suggest that changes in lateral e’ should be considered by itself since E/e’ was normal.